Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease ...
DHI Group, Inc. (DHX)
Last dhi group, inc. earnings: 2/5 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
dhigroupinc.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts , CEO: Christopher A. Viehbacher , "Biogen") announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI ® ) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). If the FDA accepts the BLA, the Prescription Drug User Fee Act (PDUFA) action date (target date for completion of examination) will be set. The BLA is based on data from the Clarity AD (Study 301) open-label extension (OLE) and modeling of observed data. If approved by the FDA, the LEQEMBI autoinjector could be used to administer LEQEMBI at home or at medical facilities, and th
Show less
Read more
Impact Snapshot
Event Time:
DHX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DHX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DHX alerts
High impacting DHI Group, Inc. news events
Weekly update
A roundup of the hottest topics
DHX
News
- DHI Group Third Quarter 2024 Earnings: US$0.004 loss per share (vs US$0.023 profit in 3Q 2023) [Yahoo! Finance]Yahoo! Finance
- Is DHI Group (DHX) Stock Undervalued Right Now? [Yahoo! Finance]Yahoo! Finance
- DHI Group, Inc. (NYSE: DHX) had its price target lowered by analysts at B. Riley from $4.00 to $3.50. They now have a "buy" rating on the stock.MarketBeat
- Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work [Yahoo! Finance]Yahoo! Finance
- DHI Group Inc (DHX) Q3 2024 Earnings Call Highlights: Navigating Challenges with Optimism for ... [Yahoo! Finance]Yahoo! Finance
DHX
Earnings
- 11/12/24 - Beat
DHX
Sec Filings
- 11/14/24 - Form SCHEDULE
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- DHX's page on the SEC website